AXIM Biotechnologies, Inc. has announced the engagement of 624 Advisors, owned and managed by Dr. Alan J. Touch, OD, as Chief Medical & Regulatory Affairs Advisor. Dr. Touch is considered a preeminent in vitro diagnostic (IVD) and companion diagnostic (CDx) subject matter expert and global regulatory specialist. This strategic move provides AXIM with enhanced technical continuity, regulatory depth, and strategic execution capability at a pivotal stage of the company's development.
Dr. Touch brings more than three decades of global leadership across diagnostics, medical devices, pharmaceuticals, and digital health. He is the original co-inventor of the first ocular diagnostic technologies acquired by AXIM and the inventor of the world's first colored contact lens. His career includes heading Clinical Affairs at Bausch & Lomb and serving as Principal Strategist for Ophthalmology, Medical Devices and Diagnostics at INC Research (Syneos Health). As Chief Science Officer of an ophthalmic contract development and manufacturing organization, he led the development of several proprietary dry eye disease products, including the first eye drop based on addressing the Inflammatory Cascade through a novel pathway.
Catalina Valencia, President and CEO of AXIM Biotechnologies, stated that Dr. Touch uniquely combines inventor-level knowledge of the company's technology with significant senior-level experience in FDA regulation, ISO quality systems, clinical development, and manufacturing readiness. His involvement strengthens AXIM's regulatory strategy, quality foundation, and clinical execution while positioning the company for efficient global expansion and long-term operational scale. As AXIM advances toward key regulatory and commercial milestones, including upcoming FDA 510(k) submissions, international regulatory expansion, and the establishment of a robust quality and manufacturing infrastructure, Dr. Touch's advisory role is designed to provide highly qualified support across these areas.
Dr. Touch's background aligns with AXIM's current efforts and upcoming goals, including his inventor-level understanding of lactoferrin and immunoassay diagnostics, deep experience across FDA, EU MDR/IVDR, and global regulatory frameworks, and proven leadership in regulatory affairs, quality systems, clinical development, and manufacturing scale-up. His engagement is expected to reduce AXIM's reliance on external consultants and accelerate readiness for commercialization and global growth.
Dr. Touch expressed his pleasure in working with AXIM at this important stage and continuing to advance technology he originally helped develop. He noted that AXIM is building a strong foundation for market-sensitive regulatory excellence and clinical credibility for its products. He looks forward to supporting the scientific, marketing, and operational team as they advance key submissions, strengthen quality systems, and prepare for long-term manufacturing and commercial success. For more information about AXIM Biotechnologies, visit https://www.aximbiotech.com.
